Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
DXCM 
DexCom Inc (DXCM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: DXCM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
26 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $102.08
1 Year Target Price $102.08
| 17 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0.54% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 29.54B USD | Price to earnings Ratio 53.06 | 1Y Target Price 102.08 |
Price to earnings Ratio 53.06 | 1Y Target Price 102.08 | ||
Volume (30-day avg) 26 | Beta 1.44 | 52 Weeks Range 57.52 - 93.25 | Updated Date 08/29/2025 |
52 Weeks Range 57.52 - 93.25 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.42 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.29% | Operating Margin (TTM) 18.37% |
Management Effectiveness
Return on Assets (TTM) 6.08% | Return on Equity (TTM) 22.83% |
Valuation
Trailing PE 53.06 | Forward PE 36.63 | Enterprise Value 29093017296 | Price to Sales(TTM) 6.87 |
Enterprise Value 29093017296 | Price to Sales(TTM) 6.87 | ||
Enterprise Value to Revenue 6.76 | Enterprise Value to EBITDA 28 | Shares Outstanding 392155008 | Shares Floating 389508217 |
Shares Outstanding 392155008 | Shares Floating 389508217 | ||
Percent Insiders 0.42 | Percent Institutions 97.49 |
Upturn AI SWOT
DexCom Inc
Company Overview
History and Background
DexCom Inc. was founded in 1999 and is headquartered in San Diego, California. It is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems. DexCom's early focus was on developing minimally invasive glucose monitoring technology. Over time, it has evolved to become a leader in the CGM market, known for its innovative products and data accuracy.
Core Business Areas
- Continuous Glucose Monitoring (CGM) Systems: DexCom's primary business is the development, manufacture, and sale of CGM systems for people with diabetes. These systems consist of a sensor inserted under the skin, a transmitter that sends glucose data wirelessly, and a receiver or smartphone app that displays the data.
Leadership and Structure
As of 2024, the leadership team is headed by Kevin Sayer, Chairman, President, and CEO. The organizational structure includes departments for research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- DexCom G7: DexCom's flagship CGM system. Market share data specific to the G7 alone is difficult to isolate, but DexCom holds a significant portion of the overall CGM market. Competitors include Abbott (FreeStyle Libre) and Medtronic. Dexcom's overall market share is roughly 60%. The G7 offers improved accuracy and ease of use compared to previous generations. It competes primarily with Abbott's FreeStyle Libre 3 and Medtronic's Guardian 4.
- DexCom G6: The previous generation of DexCom's CGM system, still widely used and supported. Specific market share data for the G6 is declining as users transition to the G7. Competitors include Abbott and Medtronic. While older, it remains relevant, offering a cost-effective alternative.
Market Dynamics
Industry Overview
The diabetes care market, particularly the CGM segment, is experiencing substantial growth driven by increasing diabetes prevalence, technological advancements, and rising awareness of the benefits of continuous glucose monitoring. The market is competitive, with established players and emerging startups.
Positioning
DexCom is a leader in the CGM market, recognized for its innovation, accuracy, and user-friendly products. Its competitive advantages include its established brand reputation, strong research and development capabilities, and extensive distribution network.
Total Addressable Market (TAM)
The global diabetes care market is expected to reach hundreds of billions of dollars. The CGM segment constitutes a significant portion of this, expected to grow rapidly. DexCom is well-positioned to capture a substantial share of this TAM.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Innovative technology
- High accuracy of CGM systems
- Extensive distribution network
- Strong customer loyalty
Weaknesses
- High cost of CGM systems relative to traditional blood glucose monitoring
- Dependence on a few key products
- Competition from other CGM manufacturers
Opportunities
- Expanding into new markets (international)
- Developing new CGM technologies (e.g., non-invasive monitoring)
- Integrating CGM data with other health platforms
- Increased awareness of the benefits of CGM systems among patients and healthcare providers
Threats
- Increasing competition from other CGM manufacturers
- Pricing pressure from insurance companies
- Regulatory changes
- Technological disruptions
Competitors and Market Share
Key Competitors
- ABT
- MDT
Competitive Landscape
DexCom's advantages include its established brand reputation, innovative technology, and strong customer loyalty. Its disadvantages include its high cost relative to competitors and dependence on a few key products.
Major Acquisitions
TypeZero Technologies
- Year: 2018
- Acquisition Price (USD millions): 56
- Strategic Rationale: To enhance DexCom's capabilities in automated insulin delivery and personalized diabetes management.
Growth Trajectory and Initiatives
Historical Growth: DexCom has experienced rapid revenue growth over the past several years, driven by increasing adoption of its CGM systems. The company has also expanded its international presence and introduced new products.
Future Projections: Analysts expect DexCom to continue to experience strong revenue growth in the coming years, driven by increasing diabetes prevalence and technological advancements. Profitability is also expected to improve.
Recent Initiatives: Recent strategic initiatives include the launch of the DexCom G7, expansion into new markets, and partnerships with other healthcare companies.
Summary
DexCom is a strong player in the CGM market due to its innovative products and established brand. Its financial performance is robust, driven by increasing revenue and profitability. DexCom should be mindful of rising competition and pricing pressures. The company's focus on innovation and strategic partnerships should continue to fuel growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Analyst Reports
- Industry Publications
- Company Website
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About DexCom Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2005-04-14 | Executive Chairman & CEO Mr. Kevin Ronald Sayer | ||
Sector Healthcare | Industry Medical Devices | Full time employees 10200 | Website https://www.dexcom.com/global |
Full time employees 10200 | Website https://www.dexcom.com/global | ||
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.